Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9988841 | Epilepsy & Behavior | 2018 | 7 Pages |
Abstract
This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Adjuvant therapy with CBD showed similar safety and efficacy for these four syndromes as reported in a diverse population of TRE etiologies. This study extended analysis of the prior report from 12â¯weeks to 48â¯weeks of efficacy data and suggested that placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in these epileptic encephalopathies.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Orrin Devinsky, Chloe Verducci, Elizabeth A. Thiele, Linda C. Laux, Anup D. Patel, Francis Filloux, Jerzy P. Szaflarski, Angus Wilfong, Gary D. Clark, Yong D. Park, Laurie E. Seltzer, E. Martina Bebin, Robert Flamini, Robert T. Wechsler, Daniel Friedman,